A Study of Pancreatic Polypeptide Response in Patients with Diabetes Mellitus with and without Pancreatic Cancer

Overview

About this study

The purpose of this study is to determine if a blood test called "pancreatic polypeptide" can help distinguish between patients with diabetes mellitus with and without pancreatic cancer.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Adult volunteers (age 18 and older) with diabetes mellitus AND:
    1. Known pancreatic cancer (i.e. type 3c DM) (n=10)   OR
    2. Type 2 DM without clinically evident pancreatic disease (n=10)
  2. An additional 5 adult volunteers WITHOUT diabetes mellitus 
    1. Age- (+/- 3 years) and gender-matched to the first five subjects enrolled with pancreatic cancer to serve as healthy controls.

Exclusion Criteria: 

  1. Inability to provide written consent
  2. Inability to fast for 12 hours
  3. Women with gestational diabetes mellitus (i.e. hyperglycemia occurring in the context of clinically diagnosed pregnancy)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Suresh Chari, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions